PMID- 36039398
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221019
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 19
IP  - 10
DP  - 2022 Oct 3
TI  - Immuno-PET Imaging of TNF-alpha in Colitis Using (89)Zr-DFO-infliximab.
PG  - 3632-3639
LID - 10.1021/acs.molpharmaceut.2c00411 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) neutralization has become increasingly 
      important in the treatment of inflammatory bowel diseases (IBD). A series of 
      monoclonal antibodies were approved in the clinic for anti-TNF-alpha therapy. 
      However, a comprehensive assessment of TNF-alpha levels throughout the colon, which 
      facilitates the diagnosis of IBD and predicts anti-TNF-alpha efficacy, remains 
      challenging. Here, we radiolabeled infliximab with long-lived radionuclides 
      (89)Zr for immuno-positron emission tomography (PET) imaging of TNF-alpha in vivo. 
      The increased TNF-alpha level was detected in the inflammatory colon of the dextran 
      sodium sulfate-induced colitis mice. The immuno-PET imaging of 
      (89)Zr-desferrioxamine-infliximab reveals a high uptake (7.1 +/- 0.3%ID/g) in the 
      inflammatory colon, which is significantly higher than in the healthy control and 
      blocked groups. The colon-to-muscle ratio reached more than 10 and was maintained 
      at a high level for 10 h after injection. The ex vivo biodistribution study also 
      verified the superior uptake in the inflammatory colon. This study provides an in 
      vivo immune-PET approach to molecular imaging of the pro-inflammatory cytokine 
      TNF-alpha. It is promising in diagnosing and predicting efficacy in both IBD and 
      other autoimmune diseases.
FAU - Yan, Ge
AU  - Yan G
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Wang, Xinyu
AU  - Wang X
AUID- ORCID: 0000-0002-9167-2077
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Fan, Yeli
AU  - Fan Y
AD  - College of Environmental Engineering, Wuxi University, Wuxi 214105, PR China.
FAU - Lin, Jianhan
AU  - Lin J
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Yan, Junjie
AU  - Yan J
AUID- ORCID: 0000-0001-8016-2277
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Wang, Lizhen
AU  - Wang L
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Pan, Donghui
AU  - Pan D
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Xu, Yuping
AU  - Xu Y
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
FAU - Yang, Min
AU  - Yang M
AUID- ORCID: 0000-0001-6976-8526
AD  - School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
AD  - NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular 
      Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220829
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Dextrans)
RN  - 0 (Radioisotopes)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - C6V6S92N3C (Zirconium)
RN  - J06Y7MXW4D (Deferoxamine)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - Cell Line, Tumor
MH  - *Colitis/chemically induced/diagnostic imaging/drug therapy
MH  - Deferoxamine
MH  - Dextrans
MH  - *Inflammatory Bowel Diseases
MH  - Infliximab
MH  - Mice
MH  - Positron-Emission Tomography/methods
MH  - Radioisotopes
MH  - Tissue Distribution
MH  - Tumor Necrosis Factor Inhibitors
MH  - Tumor Necrosis Factor-alpha
MH  - Zirconium
OTO - NOTNLM
OT  - PET imaging
OT  - TNF-alpha
OT  - inflammatory bowel diseases
OT  - infliximab
OT  - zirconium-89
EDAT- 2022/08/31 06:00
MHDA- 2022/10/05 06:00
CRDT- 2022/08/30 01:53
PHST- 2022/08/31 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/08/30 01:53 [entrez]
AID - 10.1021/acs.molpharmaceut.2c00411 [doi]
PST - ppublish
SO  - Mol Pharm. 2022 Oct 3;19(10):3632-3639. doi: 10.1021/acs.molpharmaceut.2c00411. 
      Epub 2022 Aug 29.